Key Highlights

  • The AUD 0.003 per-security final distribution is scheduled to trade ex-dividend on 13-Oct 2026.
  • The payment is 100% franked and is scheduled for 30-Oct-26.
  • At the stated price of AUD 0.140, the current Dividend data indicates a Yield of 2.12% for this distribution.
  • The current dividend schedule lists a 0.3-cent fully franked final dividend, with an ex-date of 13 October and payment on 30 October.

Star Combo Pharma Ltd (ASX:S66) is approaching an important income date, with its final distribution due to trade ex-dividend on 13-Oct 2026. The payment is AUD 0.003 per security, carries 100% franking and is scheduled to reach eligible holders on 30-Oct-26. At the quoted price of AUD 0.140, the current dividend data places the indicated yield at 2.12%. For income-focused investors, the calendar is only one part of the picture: the sustainability of future distributions ultimately depends on the Economics of the underlying health and wellness products company.

Star Combo Pharma develops, manufactures and distributes health, wellness and nutritional products. Its Business spans branded products, contract Manufacturing and distribution channels.

Star Combo’s Final Dividend Approaches

The current dividend schedule lists a 0.3-cent fully franked final dividend, with an ex-date of 13 October and payment on 30 October. At the stated AUD 0.14 share price, the indicated yield for the distribution is 2.12%. For S66, that makes the coming ex-date relevant for shareholders considering the timing of the final payment, while the broader Investment case still rests on the company’s operating or portfolio performance. For S66, an ex-dividend date determines entitlement mechanics; it does not by itself indicate whether the next distribution will be higher, lower or unchanged.

Manufacturing and Brand Economics Drive the Business

Star Combo Pharma Ltd operates as a health and wellness products company. For S66, the income profile therefore needs to be assessed using measures appropriate to that structure rather than the dividend percentage in isolation. Viewed specifically for S66, for an operating company, those measures can include earnings, margins, Cash Flow and balance-sheet capacity. Viewed specifically for S66, for an investment company, NTA, portfolio returns, profit reserves and franking balances can be more informative. Viewed specifically for S66, for a hybrid security, the contractual terms, issuer discretion and regulatory Capital conditions become especially important.

Cash Generation Will Influence Future Income Capacity

Franking is another element of the October payment. For S66, the stated 100% franking level affects the tax composition of the distribution for eligible Australian investors, although the value of franking credits depends on individual circumstances. The cash amount remains AUD 0.003 per security. For S66, investors comparing income opportunities may therefore want to separate the cash yield from any potential tax benefit and avoid treating the two as interchangeable.

What to Watch After Star Combo’s Payment

Star Combo’s next reporting period can be assessed through Revenue mix, manufacturing utilisation, margins, inventory and operating cash flow. A small dividend can be meaningful for shareholders, but future distributions need to remain supported by the company’s financial position.

For Star Combo Pharma Ltd, the October distribution should also be viewed within the company’s own capital-allocation framework. ASX:S66 holders can use subsequent results to test whether earnings, portfolio returns or security terms continue to support the current income profile. For S66, the most informative comparison will be between cash generated or realised during the next reporting period and the capital committed to operations, investments or distributions. For S66, that company-specific balance will matter more to the durability of future payments than the isolated yield attached to the present ex-dividend event.